Metrics as of 10/13/2026, 06:35 PM (Berlin time), refresh in progress.
Marker Therapeutics Stock
Marker Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Juan F. Vera
- Employees
- 5
- Market cap
- $15 M
- IPO
- 16/07/2002
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions…
Marker Therapeutics stock: price history
1D
-8.4%
1W
-8.4%
1M
-19.6%
6M
-41.8%
YTD
-37.9%
1Y
-9.3%
2Y
-65.9%
5Y
-94.2%
10Y
-98.3%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~38% weaker price swings than usual
Ask the agents about Marker Therapeutics
Analyst assessment of Marker Therapeutics
1
STRONG BUY
2
BUY
2
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 01/04/2025
Marker Therapeutics stock metrics
P/E
-1.93
P/B
1.47
EV/EBITDA
-0.47
RETURN ON EQUITY
-15.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.0%
FLOAT SHARES
13,500,509
AVG. DAILY VOLUME (30D)
77,128
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Marker Therapeutics stock
What does Marker Therapeutics do?
Marker Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Juan F. Vera, the company employs around 5 people.
The IPO was on 16/07/2002; the stock trades on NASDAQ under the ticker MRKR.
What do analysts say about Marker Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 01/04/2025).
This is an external assessment, not a statement by Market Jury.
When does Marker Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -38% stronger than usual.
Does Marker Therapeutics pay a dividend?
No, Marker Therapeutics currently does not pay a dividend.
Which stocks are comparable to Marker Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Marker Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Marker Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.